Clinical trialPhase 1 / Phase 2Completed
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 7 December 2021
- Ended
- 30 June 2026
- Enrollment
- 121 participants
- Sites
- 18
- Primary outcomes
- Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D); Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy; NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1; Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy; Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 9 October 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.